Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.43 |
| ▸ | ADH1C | P00326 | 2/20 | 0.43 |
| ▸ | ADH1A | P07327 | 2/20 | 0.43 |
| ▸ | ADH7 | P40394 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542600 | 1.00 | ADH1B (0.43) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL5541501 | 0.92 | EPHX1 (0.48) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL5541505 | 0.92 | EPHX1 (0.48) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL5535015 | 0.89 | ADH1B (0.41) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL5535010 | 0.89 | ADH1B (0.41) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL5545667 | 0.86 | — | — | |
| SCHEMBL5545668 | 0.86 | — | — | |
| SCHEMBL1485866 | 0.84 | ADH1B (0.48) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL1485856 | 0.84 | ADH1B (0.48) | ADH1BADH1CADH1AADH7EPHX1 | |
| SCHEMBL21578558 | 0.84 | ADH1B (0.48) | ADH1BADH1CADH1AADH7EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ADH1B 281/4885ADH1C 285/4885ADH1A 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.